Glaukos Schedules Q3 2026 Earnings Release Amid Key Product Launches

  • Glaukos Corporation (NYSE: GKOS) will release Q3 2026 financial results on October 28, 2026, after market close.
  • Management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) the same day.
  • The company recently launched iDose® TR, a long-duration intracameral procedural pharmaceutical for glaucoma.
  • Glaukos also markets the only FDA-approved corneal cross-linking therapy for keratoconus.

Glaukos is positioning itself as a leader in novel therapies for glaucoma, corneal disorders, and retinal diseases. The company's focus on dropless platform technologies and its recent product launches are part of a broader trend in ophthalmology towards less invasive and more effective treatments. The upcoming earnings release will provide insights into the financial impact of these strategic initiatives.

Product Adoption
The pace at which iDose TR gains market traction will be critical for Glaukos's growth.
Financial Performance
Whether Glaukos can sustain revenue growth amid increasing competition in the ophthalmology space.
Pipeline Development
How Glaukos advances its pipeline of novel dropless platform technologies for chronic eye diseases.